In plasma, the biomarkers CCL17, IL‐5, VEGF‐C, GM‐CSF and CCL26 had the most significant fold increases in plasma of patients with AD compared with healthy controls, while IL‐4 and CXCL10 had the most significant decreases. This evidence concerns the gene CSF2 and Alzheimer disease.